CARCHIP

CARCHIP will combine the expertise of the University of Twente (UTwente), chiron, Covaris, Orthros Medical, Stichting Proefdiervrij and the University of Maastricht (UM) to develop and implement a pioneering cartilage-on-chip model specifically designed for precision medicine in osteoarthritis (OA), the most common degenerative joint disease affecting more than 1.5 million Dutch. We will use primary cells and tissues obtained from osteoarthritic patients that will be endotyped using advanced mass spectrometry (MS). Endotype specific primary cell cultures will be established using animal component free chemical defined culture media. These cultures will be genetically modified with bioluminescent reporters. These modified cells will be used to establish cartilage on chip cultures using a unique platform consisting of 24 cartilage on chip devices that can be simultaneously exerted to multidirectional loading mimicking the loading of cartilage in the moving human knee joint. We will validate this model by evaluating both established anti-inflammatory drugs and novel disease-modifying agents developed by Orthros Medical. Additionally, chiron will initiate essential steps toward the commercialization of this innovative platform, which has the potential to revolutionize the development of OA treatment strategies. By integrating advanced technologies such as MS and bioluminescent imaging within a cutting-edge organ-on-chip model, the project aspires to enhance understanding of OA pathology and facilitate the development of targeted therapies. This approach not only aims to improve patient outcomes but also seeks to address the urgent need for more effective treatments for this prevalent condition which still cannot be treated effectively. Ultimately, the project will contribute significantly to the field of precision medicine, paving the way for personalized treatment plans that can better meet the needs  of individuals suffering from OA, thereby reducing the overall healthcare burden associated with this chronic disease. The integration of these methodologies represents a promising advancement in both scientific research and clinical application, fostering a new era in OA management and treatment.